 |
|
|
| |
Distribution in Cerebrospinal Fluid (CSF) of Cabotegravir (CAB) and Rilpivirine (RPV) After Intramuscular Administration of Long-Acting (LA) Injectable Suspensions in HIV-1-Infected Patients - oral talk has extra data
|
| |
| |
Reported by Jules Levn
Glasgow 2018 Oct 27-31
Scott Letendre,1 Anthony Mills,2 Debbie Hagins,3 Susan Swindells,4 Franco Felizarta,5 Jerome DeVente,6 Christopher Bettacchi,7 Yu Lou,8 Susan Ford,9 Annie Cameron,9 Kenneth Sutton,10 Jafar Sadik Shaik,11 Herta Crauwels,12 Ronald D'Amico,10 Parul Patel10
1UCSD Antiviral Research Center, San Diego, CA, USA; 2Mills Clinical Research, Los Angeles, CA, USA; 3Chatham County Health Department, Savannah, GA, USA; 4University of Nebraska Medical Center, Omaha, NE, USA; 5Office of Franco Felizarta, MD, Bakersfield, CA, USA; 6Long Beach Education and Research Consultants, Long Beach, CA, USA; 7North Texas Infectious Diseases Consultants, P.A., Dallas, TX, USA; 8PAREXEL International, Durham, NC, USA; 9GlaxoSmithKline, Research Triangle Park, NC, USA; 10ViiV Healthcare, Research Triangle Park, NC, USA; 11GlaxoSmithKline, Collegeville, PA, USA; 12Janssen Research and Development, Beerse, Belgium
|
| |
|
|
|
|
|
